Anebulo Pharmaceuticals Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Anebulo Pharmaceuticals Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|
| cash flows from operating activities: | |||
| net income | -1,653,542 | -2,717,369 | -2,480,823 |
| adjustments to reconcile net income to net cash from operating activities | |||
| stock-based compensation | 151,639 | 219,262 | 210,797 |
| amortization of loan commitment fee | 59,696 | ||
| changes in operating assets and liabilities: | |||
| prepaid expenses | -51,936 | 355,566 | -104,558 |
| accounts payable | 66,241 | -247,270 | 31,404 |
| accrued expenses | -69,476 | 544,266 | -383,645 |
| net cash from operating activities | -1,497,378 | -1,813,707 | -2,726,825 |
| cash flows from financing activities: | |||
| proceeds from issuance of common stock | |||
| payment of financing/offering costs | 0 | ||
| proceeds from issuance of common stock upon exercise of options | |||
| net cash from financing activities | 0 | ||
| net decrease in cash | |||
| cash, beginning of period | 0 | ||
| cash, end of the period | -1,497,378 | ||
| noncash investing and financing activities: | |||
| financing commitment fee funded through issuance of common stock | 0 | ||
| 4 | |||
| net increase in cash | |||
| net increase in cash and cash equivalents | -2,726,825 | ||
| cash and cash equivalents, beginning of period | 11,247,403 | ||
| cash and cash equivalents, end of the period | 8,520,578 | ||
| supplemental disclosure of noncash investing and financing activities: | |||
| offering costs included in accounts payable |
We provide you with 20 years of cash flow statements for Anebulo Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Anebulo Pharmaceuticals stock. Explore the full financial landscape of Anebulo Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Anebulo Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.